Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells

American Journal of Physiology - Endocrinology and Metabolism

Volumn 288, Issue 3 51-3, 2005, Pages

  Arnold, Julia T ^a   Le, Hanh ^a   McFann, Kimberly K ^a   Blackman, Marc R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Androgen receptor; Dehydroepiandrosterone; Estrogen receptor ; Insulin like growth factor axis; Lymph node derived cancer of prostate; Prostate specific antigen

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ESTRADIOL; ESTROGEN; MESSENGER RNA; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TESTOSTERONE;

ARTICLE; BODY FAT; BONE MASS; BONE STRENGTH; CANCER CELL CULTURE; CANCER RISK; CELL ASSAY; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; GENE EXPRESSION; HORMONAL REGULATION; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MUSCLE MASS; MUSCLE STRENGTH; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; STROMA CELL;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DEHYDROEPIANDROSTERONE; DIHYDROTESTOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; POLYMERASE CHAIN REACTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; RECEPTORS, ANDROGEN; TESTOSTERONE; TESTOSTERONE CONGENERS;

EID: 13844262629     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00454.2004     Document Type: Article

References (60)

1. Acacio BD, Stanczyk FZ, Mullin P, Saadat P, Jafarian N, and Sokol RZ. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men. Fertil Steril 81: 595-604, 2004.
2. Adams TE, Epa VC, Garrett TP, and Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57: 1050-1093, 2000.
3. Alesci S, Manoli I, and Blackman MR. Dehydrodepiandrosterone. In: Encyclopedia of Dietary Supplements, edited by Coates P, Blackman MR, Cragg G, Levine M, Moss J, and White J. New York: Marcel Dekker. In press.
4. Arnold JT, Lessey BA, Seppala M, and Kaufman DG. Effect of normal endometrial stroma on growth and differentiation in Ishikawa endometrial adenocarcinoma cells. Cancer Res 62: 79-88, 2002.
5. Bartsch W, Klein H, Schiemann U, Bauer HW, and Voigt KD. Enzymes of androgen formation and degradation in the human prostate. Ann NY Acad Sci 595: 53-66, 1990.
6. Begin D, Luthy IA, and Labrie F. Adrenal precursor C19 steroids are potent stimulators of growth of androgen-sensitive mouse mammary carcinoma Shionogi cells in vitro. Mol Cell Endocrinol 58: 213-219, 1988.
7. Bektic J, Berger AP, Pfeil K, Dobler G, Bartsch G, and Klocker H. Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. Eur Urol 45: 245-251, 2004.
8. Bruder JM, Sobek L, and Oettel M. Dehydroepiandrosterone stimulates the estrogen response element. J Steroid Biochem Mol Biol 62: 461-466, 1997.
9. Carruba G, Adamski J, Calabro M, Miceli MD, Cataliotti A, Bellavia V, Lo Bue A, Polito L, and Castagnetta LA. Molecular expression of 17 beta hydroxysteroid dehydrogenase types in relation to their activity in intact human prostate cancer cells. Mol Cell Endocrinol 131: 51-57, 1997.
10. Castagnetta LA, Carruba G, Traina A, Granata OM, Markus M, Pavone-Macaluso M, Blomquist CH, and Adamski J. Expression of different 17beta-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells. Endocrinology 138: 4876-4882, 1997.
11. Castagnetta LA, Miceli MD, Sorci CM, Pfeffer U, Farruggio R, Oliveri G, Calabro M, and Carruba G. Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 136: 2309-2319, 1995.
12. Chang HC, Miyamoto H, Marwah P, Lardy H, Yeh S, Huang KE, and Chang C. Suppression of delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells. Proc Natl Acad Sci USA 96: 11173-11177, 1999.
13. Cohen P, Peehl DM, Graves HC, and Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142: 407-415, 1994.
14. Cohen P, Peehl DM, and Rosenfeld RG. The IGF axis in the prostate. Horm Metab Res 26: 81-84, 1994.
15. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, and Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 76: 1031-1035, 1993.
16. Comstock GW, Gordon GB, and Hsing AW. The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate. Cancer Epidemiol Biomarkers Prev 1: 219-221, 1993.
17. Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, and Vessella RL. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clin Cancer Res 8: 1003-1007, 2002.
18. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, and Klocker H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7: 1541-1550, 1993.
19. De Coster R, Wouters W, and Bruynseels J. P450-dependent enzymes as targets for prostate cancer therapy. J Steroid Biochem Mol Biol 56: 133-143, 1996.
20. De Launoit Y, Veilleux R, Dufour M, Simard J, and Labrie F. Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 51: 5165-5170, 1991.
21. El-Alfy M, Luu-The V, Huang XF, Berger L, Labrie F, and Pelletier G. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology 140: 1481-1491, 1999.
22. Geller J. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Semin Oncol 12: 28-35, 1985.
23. Gingras S and Simard J. Induction of 3beta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines. Endocrinology 140: 4573-4584,. 1999.
24. Gnanapragasam VJ, McCahy PJ, Neal DE, and Robson CN. Insulin-like growth factor II and androgen receptor expression in the prostate. BJU Int 86: 731-735, 2000.
25. Goossens K, Esquenet M, Swinnen JV, Manin M, Rombauts W, and Verhoeven G. Androgens decrease and retinoids increase the expression of insulin-like growth factor-binding protein-3 in LNCaP prostatic adenocarcinoma cells. Mol Cell Endocrinol 155: 9-18, 1999.
26. Gregory CW, Kim D, Ye P, D'Ercole AJ, Pretlow TG, Mohler JL, and French FS. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology 140: 2372-2381, 1999.
27. Harman SM, Metter EJ, Blackman MR, Landis PK, and Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 85: 4258-4265, 2000.
28. Hobisch A, Hittmair A, Daxenbichler G, Wille S, Radmayr C, Hobisch-Hagen P, Bartsch G, Klocker H, and Culig Z. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J Pathol 182: 356-361, 1997.
29. Horoszewicz J, Leong S, Kawinski E, Karr J, Rosenthal H, Chu T, Mirand E, and Murphy G. LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818, 1983.
30. Isaacs JT. The aging ACI/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis. Cancer Res 44: 5785-5796, 1984.
31. Klein H, Bressel M, Kastendieck H, and Voigt KD. Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer. Am J Clin Oncol 11, Suppl 2: S30-S36, 1988.
32. Koh E, Kanaya J, and Namiki M. Adrenal steroids in human prostatic cancer cell lines. Arch Androl 46: 117-125, 2001.
33. Labrie F, Belanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez JL, and Candas B. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids 63: 322-328, 1998.
34. Labrie F, Luu-The V, Labrie C, and Simard J. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol 22: 185-212, 2001.
35. Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, and Vidaud M. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61: 1919-1926, 2001.
36. Maggiolini M, Donze O, Jeannin E, Ando S, and Picard D. Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha. Cancer Res 59: 4864-4869, 1999.
37. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, and Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76: 1115-1118, 1997.
38. Martel C, Meiner MH, Gagne D, Simard J, and Labrie F. Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol 104: 103-111, 1994.
39. Martin C, Ross M, Chapman KE, Andrew R, Bollina P, Seckl JR, and Habib FK. CYP7B generates a selective estrogen receptor beta agonist in human prostate. J Clin Endocrinol Metab 89: 2928-2935, 2004.
40. Martin-Du Pan RC. [Are the hormones of youth carcinogenic?] Ann Endocrinol (Paris) 60: 392-397, 1999.
41. Negri-Cesi P, Poletti A, Colciago A, Magni P, Martini P, and Motta M. Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. Prostate 34: 283-291, 1998.
42. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, and . Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61: 6276-6280, 2001.
43. Oesterling JE, Epstein JI, and Walsh PC. The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. J Urol 136: 1030-1034, 1986.
44. Orentreich N, Brind JL, Vogelman JH, Andres R, and Baldwin H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 75: 1002-1004, 1992.
45. Peehl DM, Cohen P, and Rosenfeld RG. The insulin-like growth factor system in the prostate. World J Urol 13: 306-311, 1995.
46. Poortman J, Prenen JA, Schwarz F, and Thijssen JH. Interaction of delta-5-androstene-3beta, 17beta-diol with estradiol and dinydrotestosterone receptors in human myometrial and mammary cancer tissue. J Clin Endocrinol Metab 40: 373-379, 1975.
47. Rajah R, Khare A, Lee PD, and Cohen P. Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. J Endocrinol 163: 487-494, 1999.
48. Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE, Kelloff GJ, and McCormick DL. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res 59: 3084-3089, 1999.
49. Robinson EJ, Neal DE, Collins AT, Mitchen J, Oberley T, and Wilding G. Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Extended culturing of androgen-responsive human primary epithelial prostate cell isolates by continuous treatment with interstitial collagenase. Prostate 37: 149-160, 1998.
50. Schwartz AG and Pashko LL. Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. J Cell Biochem Suppl 22: 210-217, 1995.
51. Shughrue PJ, Lane MV, Scrimo PJ, and Merchenthaler I. Comparative distribution of estrogen receptor-alpha (ER-alpha) and beta (ER-beta) mRNA in the rat pituitary, gonad, and reproductive tract. Steroids 63: 498-504, 1998.
52. Signoretti S and Loda M. Estrogen receptor beta in prostate cancer: brake pedal or accelerator? Am J Pathol 159: 13-16, 2001.
53. Soto AM, Lin TM, Sakabe K, Olea N, Damassa DA, and Sonnenschein C. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response. Oncol Res 7: 545-558, 1995.
54. Svec F and Porter JR. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med 218: 174-191, 1998.
55. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, and Balk SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393-1398, 1995.
56. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, and Mulder E. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41: 665-669, 1992.
57. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, and Gustafsson JA. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 98: 6330-6335, 2001.
58. Williams MR, Dawood T, Ling S, Dai A, Lew R, Myles K, Funder JW, Sudhir K, and Komesaroff PA. Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab 89: 4708-4715, 2004.
59. Yeap BB, Krueger RG, and Leedman PJ. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology 140: 3282-3291, 1999.
60. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, and Feldman D. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 162: 2192-2199, 1999.